23^rd World Congress on Cancer and Diagnostics August 23-24, 2023 Toronto, Canada

Xiuwei Yang completed his post-doctoral fellowship from Manitoba Cancer Treatment & Research Foundation in cancer biology.He presently working as assistant professor in department of Molecular & Biomedical Pharmacology at University of Kentucky.He holds a membership for American Association for Cancer Research (AACR) and The American Society for Biochemistry and Molecular Biology (ASBMB).

Biological, pathological and signaling roles of cell adhesion molecules in tumor onset or recurrence, progression and metastasis. Potential biomarkers or therapeutic targets for cancer diagnosis and treatment.

Dr Ramin Sadri undertook his undergraduate studies in Physiology and Biochemistry at the University of Reading, UK. He developed interest in hormone-dependent cancers and obtained a Ph.D. in pharmacology at Cardiff University, UK. After gaining a research fellowship from the Royal Society, UK, he embarked on postdoctoral work at the University of Florence, Italy. This was followed by periods of postdoctoral research at Baylor College of Medicine, USA, Institut Curie in France, and at the Imperial Cancer Research Fund, UK.

In the last 12 years he developed interest in genomics working at Cancer Research UK and The Francis Crick Institute. Currently he is based at UCL Cancer Institute in London, UK.

Wojciech Dyszkiewicz is a Professor of Thoracic Surgery in Department of Thoracic Surgery, Department of Thoracic Surgery, Poland. He id the official member of Society of Polish Surgeons, European Society of Thoracic Surgeons, Polish Cardiology Society and Polish Group of Lung Cancer. He has published over 120 original papers published in national and international medical journals.

Lung cancer, Surgery for mediastinal tumors, Surgery for funnel chest, Surgery for funnel chest and Cardiac surgery for valvular diseases.

Holly Brunton is currently a Research Associate in the laboratory of Professor Andrew Biankin at the Wolfson Wohl Cancer Research Centre, which is part of the Institute of Cancer Sciences at the University of Glasgow. Primary research efforts are focused towards advancing genotype guided stratified therapy for pancreatic cancer. Holly completed her doctorate in Biochemistry at the University of Sussex in 2011, studying DNA double strand break repair in the context of higher order chromatin structure. Holly joined the National Institute of Radiological Sciences, Japan, in 2011 as a Research Associate analyzing the effect of heavy-ion radiation on cell cycle arrest. In 2012, Holly moved to Manchester to work within the Molecular Cancer Studies department at the University of Manchester. Here, she investigated mechanisms of resistance to targeted cancer therapy in melanoma.

Cancer Biology Oncology Targeted cancer therapy Personalised medicine DNA damage

Hem D. Shukla is Research Scientist in Department of Pharmaceutical Sciences at University of Maryland and adjunct Professor of Genomics in Notredame of Maryland University. He has also worked as Research Faculty in Department of Biology at Johns Hopkins University. Dr. Shukla has worked on proteomic analysis of oxidative stress response in BxPC-3 pancreatic cell lines and identification of biomarkers for pancreatic cancer. He has worked on “The Nrf2 mediated antioxidant defense against oxidative stress in pancreatic cancer cell lines and targets for therapeutic intervention”. He has shown elevated level of Nrf2 transcriptional factor in pancreatic cancer cell lines under oxidative stress which is phosphorylated by protein kinase C and affects phosphatidylinositol 3-kinase and MAP kinase pathways. After phosphorylation, Nrf2 translocates to the nucleus, binds AREs and transactivates detoxifying enzymes and antioxidant enzymes, such as glutathione S-transferase, and superoxide dismutase. The IPA analysis has suggested a potential role of Nrf2 under oxidative stress conditions.

Proteomic analysis of oxidative stress response in BxPC-3 pancreatic cell lines Identification of biomarkers for pancreatic cancer Nrf2 mediated antioxidant defense against oxidative stress in pancreatic cancer cell lines

Dr. Massimo Libra is associated professor of general pathology at the Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania (Catania, Italy). He is director of the Translational Oncology & Functional Genomics Laboratory at the same Department. Dr. Massimo Libra received his M.D. degree from the University of Catania in 1995. Dr. Libra was a post-fellow at the National Cancer Institute in Aviano (Italy) during the Specialization in Oncology. In 2002, he received his Ph.D. degree in Oncology from the University of Catania. He was visiting scientist at the UCLA and East Carolina University. His research is focused on defining the molecular mechanisms involved in the genesis and progression of tumors and the identification of new elements for a more effective diagnosis, prognosis and treatment of cancer. In details, he studies the activation of Ras-Raf-MEK-ERK-MAPK and PI3K/PTEN/AKT/mTOR pathways and their pharmacological targeting, the cross-talk between the p53 pathway and other pathways (Yin Yang 1, Stathmin), associated with the development of cancer, the study of the tumor microenvironment (NGAL, OPN, MMPs, cytokines).

Molecular mechanisms involved in the genesis and progression of tumors Identification of new elements for a more effective diagnosis, prognosis and treatment of cancer Activation of Ras-Raf-MEK-ERK-MAPK PI3K/PTEN/AKT/mTOR pathways Study of the tumor microenvironment

Hideki Shimodaira is an Associate Professor in Department of Clinical Oncology, Institute of Development, Aging and Cancer (IDAC), Tohoku University. He was appointed as Senoior Assistant Professor in Department of Clinical Oncology, Tohoku University Hospital in year 2009-2014. He worked as an Assistant Professor in Department of Clinical Oncology, Institute of Development, Aging and Cancer (IDAC), Tohoku University. He recieved his Postdoctoral Fellowship at Ludwig Institute for Cancer Research, University of California San Diego, School of Medicine. He was awarded to be a Board certified member of the Japanese Board of Cancer Therapy and Japanese Society of Human Genetics in year 2009 and 2012.

Clinical Oncology Internal Medicine Medical Oncology Cancer Therapy Human Genetics

Dr. James A Radosevich is a Professor in the School of Dental Medicine at the University of Illinois at Chicago (UIC). From 1983 to 2004 he was an Assistant/Associate Professor and a Certified Clinical Investigator (ICH) at Northwestern University Medical School. He has consulted for numerous companies over the last thirty years, received numerous national grants/awards, and been involved in all aspects of drug development and clinical trials. Dr. Radosevich has been part of six start-up biotechnology/medical companies over the past thirty years and has a history of consistently beating performance milestones. He has held the positions of President, CEO, Chief Scientific Officer, and was the founder for five of these companies. Dr. Radosevich earned a B.S. degree in Biology at Bradley University in Peoria, Illinois in 1978 and a Ph.D. in Experimental Pathology at UIC in 1983. He completed his postdoctoral training at Northwestern University in Tumor Cell Biology, where he established his expertise in immune recognition, immune response, and various molecular and biochemical approaches in understanding the morphology, physiology, and cell biology of human cancer. He has edited three books, and has over four hundred published scientific papers, book chapters and abstracts, as well as 12 patents.

Tumor Cell Biology Immune recognition Immune response Molecular and biochemical approaches in understanding the morphology, physiology, and cell biology of human cancer

Assistant professor at department of pathology

Cancer Immunotherapy, Biomedical science

Dr. Douglas P. Malinowski is a BD Fellow, the Global Head of Scientific Affairs and the Chief Scientific Officer for BD Diagnostics - Women’s Health and Cancer. His current responsibilities include leading the technology strategy, the innovation programs and the Office of Scientific Affairs for the Women’s Health and Cancer business. These responsibilities encompass molecular oncology, cervical disease screening, HPV genotyping and cytopathology.

Molecular diagnostics, Biomarkers, Translational research, Human Papillomavirus (HPV) biology, Gynecologic cancers (cervical, ovarian, endometrial).

I have a PhD in Biochemistry (Kolkata, India, 2001) and have over nine years of post-doctoral experience first at the University of Nebraska Medical Center and then at the University of Pittsburgh. In 2010, I got promoted to Research Instructor at the Department of Otolaryngology, University of Pittsburgh and in 2012 to the position of Research Assistant Professor. Presently my research focusses on understanding epigenetic changes in cancer, development of therapeutic strategies based upon epigenetic alterations and development of alterations in DNA methylation for use as predictive biomarkers and early detection of lung cancer. My previous research was focused primarily on identifying new molecularly targeted strategies for head and neck squamous cell carcinoma (HNSCC) therapy. I have prior experience working in the area of glaucoma where we have looked at the effect of a novel therapeutic agent in the delay of progression of glaucoma. I have over 30 peer-reviewed publications.

Understanding and characterizing epigenetic changes in cancer as well as focusing on molecular targeted therapies in targeting novel molecules that are upregulated in cancer.

Roberto Scatena completed his specialistion in internal medicine from Tor Vergata University.He is presently working as an associate professor in department of medicine at Catholic University of Rome.He holds memberships for Società Italiana Biochimica Clinica (SIBIOC),Società Italiana Biochimica e Biologia Molecolare (SIB),MiPsociety (Mitochondrial Physiology) – Unit Mitochondria and Cancer.He is also a national coordinator for the research group “ Cell Differentiation and Neoplastic Transformation” by Italian Society of Biochemistry and Molecular Biology.

Cancer cell metabolism, Cancer Stem Cell, Mitochondrial Medicine, Cancer biomarkers

Dr. Ahn earned her Ph.D. from the University of Alabama at Birmingham, USA, after completing her undergraduate work in Seoul National University, South Korea. She did her postdoctoral research in Scripps Research Institute and University of California San Diego with special interests in molecular mechanisms of leukemia and roles of RNA splicing. After serving as Assistant Project Scientist at the Moores Cancer Center of the University of California San Diego, Dr. Ahn joined Mitchell Cancer Institute, University of South Alabama as an Assistant Professor in 2012. She heads a lab that is interested in transcriptional control, RNA splicing and non-coding RNA regulation in cancer development and progression, with the goal of identifying novel drug targets for cancer therapy. She is the recipient of numerous professional awards, including international awards for research in leukemia and allied conditions from Lady TATA Memorial Trust.

Mechanisms of RNA splicing and epigenetic controls,Roles of non-coding RNAs in cancer development and progression,Regulation of transcription factors in leukemia and breast cancer,Identification of novel targets for cancer therapy.

Mohammadreza Khanmohammadi completed his Ph.D in Analytical Chemistry from Shahid Beheshti University, Tehran, Iran.He holds membership in American Chemical Society,Iranian Chemical Society and National Elite Foundation, Iran.He had received several honors and awards.

Spectroscopy, Applied Chemometrics, Chemoinformatics, Surfactants & Detergents, Online Controlling Systems, Nanotechnology

Nahum J. Duker completed his post-doctoral fellowship from New York University Medical Center. He presently working as professor in department of Pathology and Laboratory Medicine and Fels Institute for Cancer Research and Molecular Biology at Temple University School of Medicine. He is scientific consultant for Cancer Information Dissemination and Analysis Center and The Committee for the Scientific Investigation of the Claims of the Paranormal.

Cancer, Cellular Proliferation,Molecular Pathology of Carcinogenic DNA Damage, Hepatocarcinogenesis

He graduated in Medicine and Surgery from the Universidad Autónoma Barcelona in 1988. He specializes in Nuclear Medicine, has the Diploma of Expert in Radiopharmacy. Fellow conducted a PET at MD.Anderson Houston.TX-USA in 1993 and obtained the European Board in Nuclear Medicine in 2008. He made a Master Integrated Health Services in ESADE during 2002-2003. He obtained a doctorate from the Universidad Barcelona,Cum Laude, in 2015 with the title "11C-Choline PET/CT in Prostate Cancer." He was Chief of Nuclear Medicine at CTD-Hospital Mutua Terrassa from 1994-2000. He is currently Head of the PET Unit CETIR-ERESA since 2006, where he was also Medical Assistant from 2000-2006. He is a member of the executive committee of PET Group of the Sociedad Española Medicina Nuclear, the Drafting Committee of the Revista Española Medicina Nuclear, National Advisor Oncology Committee of the European Association Nuclear Medicine and member of honor of the Sociedad Española Diagnóstico Imagen SEDIA – SERAM.

Nuclear Medicine,Cancer.

Kirillov V.A. graduated from the Belarusian State University. In 1979 maintained a thesis for PhD degree, in 1991 – Doctor's of Science. V. Kirillov – head of the Laboratory of Cytology at the Research Institute for Radiation Medicine from 1988 to 2002 and than at the Belarusian State Med-ical University since 2003 till present. He has trained 5 PhDs and 1 Master. More than 40 years of scientific experience. The author of more than 200 printed scientific works and 31 patents. Partici-pated in more than 50 international scientific conferences. He is an editorial board member of the national journals “Proceedings of the National Academy of Science of Belarus”.

Cancer, cytopathology, cytology diagnosis, morphometry, expert system, image processing.